← Back to Search

JAK2 V617F mutation positive MPN patients for Myeloproliferative Neoplasms

N/A

Waitlist Available

Led By Aleksander Chojecki, MD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Summary

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Eligible Conditions

Myeloproliferative Neoplasms

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Expression levels of TLR 2 and TLR 4

Secondary study objectives

History of thrombosis

Plasma levels of inflammatory cytokines

Plasma levels of inflammatory cytokines following incorporation of TLR ligands

Side effects data

From 2017 Phase 2 trial • 14 Patients • NCT01437488

64%

Fatigue

43%

Diarrhea

36%

Constipation

36%

Anemia

36%

Nausea

21%

Creatinine Increased

21%

Lightheadedness

21%

Vomiting

21%

Hypokalemia

14%

Abdominal Pain

14%

Back Pain

14%

Dizziness

14%

Fever

14%

Flu-Like symptoms

14%

Hypomagnesia

14%

Pinching sensation around port

14%

Shortness of Breath

14%

URI

14%

Abdominal cramping

14%

Insomnia

14%

Thrombocytopenia

Bloating

Blood in Bilirubin increased

Decreased Appetite

Dry Skin

Sacral Edema

Tearing

Tinnitus

Acid Reflux

INR increased

Embolic stroke

Pulmonary Embolism

Anorexia

Anxiety

Dyspnea

Dysuria

Fall

Flatulence

Foot Pain

Hematoma

Leg pain

Loose Stools

mild-mod Congestion

Neutrophil count decreased

Neuropathy

Rib pain

Throat discomfort

Urinary incontinence

Urinary Tract Obstruction

Worsening pain

Vision changes

Hypoxia

Abdominal distention

Alkalosis

Bladder Spasm

Blurred Vision

Bone Pain

Cabazitaxel Infusion reaction

Change in Taste

Epigastric Pain

Hematuria

Hypophosphatemia

Hypertension

Pain in Pelvis

Paresthesia bilateral feet

Perioral numbness

Peripheral Neuropathy

Weakness

Weight loss

Tachycardia

Bleeding Gums

PTT prolonged

Pyelonephritis

Rash

100%

80%

60%

40%

20%

Study treatment Arm

Cabazitaxel

Trial Design

2Treatment groups

Experimental Treatment

Group I: JAK2 V617F mutation positive MPN patientsExperimental Treatment1 Intervention

Patients with MPN disease with a JAK2 mutation

Group II: CALR-mutation positive patientsExperimental Treatment1 Intervention

Patients with MPN disease with a CALR mutation

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Brookdale University Hospital Medical CenterOTHER

8 Previous Clinical Trials

3,163 Total Patients Enrolled

Wake Forest University Health SciencesLead Sponsor

1,266 Previous Clinical Trials

1,013,672 Total Patients Enrolled

Atrium Health Levine Cancer InstituteOTHER

24 Previous Clinical Trials

1,804 Total Patients Enrolled

~23 spots leftby Feb 2026

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.